FDA has approved Wegovy, Trulicity, Saxenda, Victoza and Mounjaro for this, in the words of each label below. STEP TEENS (Semaglutide): At week 68, BMI fell 16.1% on semaglutide against a rise of 0.6% on placebo in adolescents with obesity. Stomach side effects were more common (62% against 42%), and 4% on semaglutide had gallstones against none on placebo. ClinicalTrials.gov lists 65 trials of these medicines on it: 19 with posted results and 20 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 5, 2026.
The approved use, word for word from each current label.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 201 people · Better than the comparison · Placebo-controlled randomized trial
At week 68, BMI fell 16.1% on semaglutide against a rise of 0.6% on placebo in adolescents with obesity. Stomach side effects were more common (62% against 42%), and 4% on semaglutide had gallstones against none on placebo.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 24 | 3 | 12 |
| Liraglutide | 14 | 6 | 0 |
| Exenatide | 12 | 7 | 0 |
| Tirzepatide | 6 | 2 | 3 |
| Dulaglutide | 5 | 1 | 2 |
| Mazdutide | 2 | 0 | 1 |
| Orforglipron | 2 | 0 | 2 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Liraglutide | Phase 3 | 251 | Change in BMI SDS (Week 0, Week 56) (SDS score), Week 0, week 56. Liraglutide 3.0 mg: -0.25; Placebo: -0.02. |
| NCT04102189A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Semaglutide | Phase 3 | 201 | Change in Body Mass Index (BMI) (Percentage [%]) (Percentage change of BMI), Baseline (week 0), week 68. Semaglutide 2.4 mg: -16.2; Placebo: -0.1. |
| AWARD-PEDSA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Dulaglutide | Phase 3 | 154 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 (percentage of HbA1C), Baseline, Week 26. Placebo: 0.5; Pooled Dulaglutide: -0.7. |
| Ellipse™Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes | Liraglutide | Phase 3 | 135 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of HbA1c), Week 0, week 26. Liraglutide 1.8 mg: -0.643; Placebo: 0.415. |
| PIONEER TEENSA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Semaglutide | Phase 3 | 132 | Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point (Percentage point), Baseline (Week 0), Week 26. Oral Semaglutide: -1.0; Placebo: -0.3. |
| NCT00658021Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes | Exenatide | Phase 3 | 122 | Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 (percentage (%HbA1c)), Baseline (Day 1) and Week 28. Total Exenatide Twice Daily (EBID): 0.11; Placebo: 0.38. |
| SURPASS-PEDSA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Tirzepatide | Phase 3 | 99 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (percentage of HbA1c), Baseline, Week 30. Pooled Doses of Tirzepatide (5 mg, 10 mg): -2.03; Placebo: -0.23. |
| APPLELiver and Fat Regulation in Overweight Adolescent Girls | Exenatide | Phase 2/3 | 92 | Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57. |
| NCT01554618Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes | Exenatide | Phase 3 | 84 | Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) (percentage (% HbA1c)), Baseline (Week 0) and Week 24. Controlled Assessment Period - Exenatide: -0.36; Controlled Assessment Period - Placebo: 0.49. |
| TEALTreating PCOS With Semaglutide vs Active Lifestyle Intervention | Semaglutide | Phase 2/3 | 60 | Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84. |
| NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Liraglutide | Phase 3 | 56 | Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks (SDS score), Week 0, Week 16. Part A: Liraglutide: -0.18; Part A: Placebo: -0.18; Part B: Liraglutide: -0.50; Part B: Placebo: -0.48; Part A+B: Liraglutide: -0.33; Part A+B: Placebo: -0.29. |
| NCT02516657Liraglutide in Adolescents With Type 1 Diabetes | Liraglutide | Phase 3 | 5 | On ClinicalTrials.gov |
| NCT02496611Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity | Exenatide | Phase 2 | 100 | Body Mass Index (percentage (body mass index)), 52 weeks. Weight Loss Maintenance Without Pharmacotherapy: 10.1; Weight Loss Maintenance With Pharmacotherapy: 4.6. |
| NCT04883346Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Liraglutide | Phase 2 | 34 | On ClinicalTrials.gov |
| NCT01237197Exenatide in Extreme Pediatric Obesity | Exenatide | Phase 2 | 26 | Percent Change From Baseline in Body Mass Index at 3-months (percentage of change in BMI), Baseline and 3-months. Exenatide: -2.9; Placebo Injection: -0.15. |
| NCT02960659Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes | Liraglutide | Phase 1/2 | 24 | Change in Absolute Gluconeogenesis From Baseline to 12 Weeks (mg/kg LBM/min), Baseline to 12 weeks. Metformin: 0.018; Metformin and Liraglutide: -0.050. |
| NCT00886626GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children | Exenatide | Phase 2 | 12 | Change in Body Mass Index (BMI) (change in kg/m^2), 3-month. Exenatide: -0.9; Control: 0.84. |
| NCT05696847A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity | Tirzepatide | Phase 1 | 28 | Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) (Percentage of participants), Baseline through Week 14, TEAE. Cohort 1: Placebo (BW >=50 kg): 0.0; Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg): 83.3; Cohort 2: Placebo (BW <50 kg): 0.0; Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg): 85.7; Cohort 3: Placebo (BW 40 to 60 kg): 33.3; Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg): 100.0. |
| NCT01444898Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome | Exenatide | Not phased | 10 | On ClinicalTrials.gov |
The registry page names each site and who can enroll. Ask your clinician before joining one.
The 15 largest of 20 recruiting.
Randomized trial · Diabetologia · Aug 19, 2026 · Adly AAM et al.
Meta-analysis · Pharmacol Res · Jul 4, 2026 · Li Y et al.
Systematic review · Diabetes Res Clin Pract · Jun 28, 2026 · Soliman AT et al.
Randomized trial · Obes Facts · Jun 2, 2026 · Stenlid R et al.
Randomized trial · Diabetes Care · Jun 1, 2026 · Arslanian S et al. · cited by 5
Meta-analysis · Diabetes Obes Metab · May 11, 2026 · Silva CFXCA et al. · cited by 1
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
STEP TEENS (Semaglutide, 201 people): At week 68, BMI fell 16.1% on semaglutide against a rise of 0.6% on placebo in adolescents with obesity. Stomach side effects were more common (62% against 42%), and 4% on semaglutide had gallstones against none on placebo.
Yes: Wegovy, Trulicity, Saxenda, Victoza and Mounjaro. Wegovy's label: to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition.
Plans decide, and they usually tie coverage to a medicine's approved uses, so Wegovy, Trulicity, Saxenda, Victoza and Mounjaro are the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.
Semaglutide, with 24 registered trials on it, then Liraglutide with 14. More trials do not mean better results: read what each posted.
20 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.